PubMed · 1997 · 41 citations · 0 references
Life SciencesImmunologyPharmacotherapyCardiac TransplantationImmunotherapyTransplant ImmunologyAllograft RejectionHeart TransplantationImmunosuppression ManagementImmunosuppressive TherapyTransplant ImmunotherapyTransplant RejectionAcute Cardiac Allograft RejectionBiologic Therapies In TransplantationCyclophosphamide-based ConditioningHeart Transplant RejectionLong-term ImmunosuppressionPost-transplant CyclophosphamidePost-transplant Immunosuppression
A highly human leukocyte antigen-sensitized heart transplant candidate underwent immunomodulation with intravenous gamma globulin and cyclophosphamide. His panel reactive antibody screen fell from 64% to 14%. He underwent successful orthotopic heart transplantation with a histoincompatible, T-cell cross-match-negative heart without the development of hyperacute rejection. The combination of intravenous gamma globulin and cyclophosphamide may be a simple and effective means to overcome the human leukocyte antigen-barrier in sensitized heart transplant candidates.